Asprosin Neutralizing Antibodies as a Treatment for Metabolic Syndrome
Mishra, I.; Duerrschmid, C.; Ku, Z.; Xie, W.; Silva, E. S.; Hoffman, J.; Xin, W.; Zhang, N.; An, Z.; Chopra, A.
Show abstract
Recently, we discovered a new glucogenic and centrally-acting orexigenic hormone - asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and importantly, its genetic loss results in reduced appetite, leanness and robust insulin sensitivity, leading to protection from MS. Here we demonstrate that anti-asprosin monoclonal antibodies (mAbs) are a dual-effect pharmacologic therapy that targets the two key pillars of MS - over-nutrition and the blood glucose burden. Anti-asprosin mAbs from three distinct species lowered appetite and body weight, and improved blood glucose in a dose-dependent and epitope-agnostic fashion in three independent MS mouse models, with an IC50 of [~]1.5 mg/kg. In addition, mAb treatment ameliorated MS associated dyslipidemia and hepatic dysfunction. The mAbs displayed half-life of over 3 days in vivo, with equilibrium dissociation-constants in picomolar to low nanomolar range. This evidence paves the way for further development towards an investigational new drug application and subsequent human trials for treatment of MS, a defining physical ailment of our time.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Non-canonical Metabolic and Molecular Effects of Calorie Restriction Are Revealed by Varying Temporal Conditions 95%
- Target deconvolution of an insulin hypersecretion-inducer acting through VDAC1 with a distinct transcriptomic signature in beta-cells 94%
- Hepatocyte Membrane Potential Regulates Serum Insulin and Insulin Sensitivity by Altering Hepatic GABA Release 94%
Similar papers in this journal
- Red Blood Cells Serve as a Primary Glucose Sink to Improve Glucose Tolerance at Altitude 93%
- Human skeletal muscle CD90+ fibro-adipogenic progenitors are associated with muscle degeneration in type 2 diabetes patients 93%
- Targeting pathogenic Lafora bodies in Lafora disease using an antibody-enzyme fusion 93%
Similar papers in this journal
- Mesenchymal-specific Alms1 knockout in mice recapitulates key metabolic features of Alström Syndrome 95%
- Single-agent Foxo1 inhibition normalizes glycemia and induces gut β-like cells in streptozotocin-diabetic mice 95%
- Chemical induction of gut β-like-cells by combined FoxO1/Notch inhibition as a glucose-lowering treatment for diabetes 94%
Similar papers in this journal
- Systemic LSD1 inhibition prevents aberrant remodeling of metabolism in obesity 94%
- β-cell SENP1 facilitates responsiveness to incretins and limits oral glucose intolerance in high fat fed mice 93%
- Polysaccharide A-dependent opposing effects of mucosal and systemic exposures to human gut commensal Bacteroides fragilis in type 1 diabetes 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.